Portola Pharmaceuticals (PTLA) Stock Price, News & Analysis

Company Overview

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness. It is also advancing cerdulatinib, a dual spleen tyrosine kinase and janus kinases inhibitor in development for the treatment of hematologic cancers. In addition, the company is developing PRT2761, a Syk inhibitor that has completed Phase II clinical trial for the treatment for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Millennium Pharmaceuticals, Inc.; SRX Cardio; LLC; Ora; and Astellas Pharma Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $18.03 to $18.03
• 50-Day Range: $18.03 to $18.03
• 52-Week Range: $5.31 to $31.73
• Volume: N/A
• Average Volume: 3.17 million shs
• Market Capitalization: $1.42 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PTLA Stock Analysis - Frequently Asked Questions

How were Portola Pharmaceuticals' earnings last quarter?

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) released its quarterly earnings data on Monday, May, 11th. The biopharmaceutical company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.74) by $0.14. The company's revenue for the quarter was up 18.9% compared to the same quarter last year.

What other stocks do shareholders of Portola Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Portola Pharmaceuticals investors own include Lexicon Pharmaceuticals (LXRX), Novavax (NVAX), Iovance Biotherapeutics (IOVA), Amarin (AMRN), Editas Medicine (EDIT), Exelixis (EXEL) and Geron (GERN).

Company Calendar

• Last Earnings: 5/11/2020
• Today: 8/22/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:PTLA
• CIK: 1269021
• Web: www.portola.com
• Phone: 650-246-7000
• Fax: N/A
• Employees: 324
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($4.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$290.66 million
• Net Margins: -232.73%
• Pretax Margin: N/A
• Return on Equity: -267.86%
• Return on Assets: -54.66%

Debt

• Debt-to-Equity Ratio: 4.77
• Current Ratio: 4.87
• Quick Ratio: 4.82

Sales & Book Value

• Annual Sales: $116.64 million
• Price / Sales: 12.13
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.67 per share
• Price / Book: 10.80

Miscellaneous

• Outstanding Shares: 78,484,000
• Free Float: N/A
• Market Cap: $1.42 billion
• Optionable: Optionable
• Beta: 2.32